Mercaptamine bitartrate - Mylan/Orphan Europe

Drug Profile

Mercaptamine bitartrate - Mylan/Orphan Europe

Alternative Names: Cystagon; Cysteamine - Mylan/Orphan Europe; Cysteamine bitartrate

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mylan; Orphan Europe
  • Developer Alphapharm; Mylan; Orphan Europe
  • Class Mercaptoethylamines; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Nephropathic cystinosis
  • Discontinued Unspecified

Most Recent Events

  • 26 Oct 2017 Chemical structure information added
  • 31 Dec 2008 Mercaptamine bitartrate oral is still in phase II/III trials for Undefined indication in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top